EMERGENCE OF BENZOTHIAZOLE AND ITS DERIVATIVES AS A POTENTIAL ANTIDIABETIC PROBE
-
Published:2020-10-08
Issue:07
Volume:57
Page:7-18
-
ISSN:0019-462X
-
Container-title:INDIAN DRUGS
-
language:
-
Short-container-title:IND. DRU.
Author:
Bainsal Neeraj,Singh Jitender,Thakur Aman
Abstract
Development of drugs against diabetes has always remained a big challenge among the medicinal chemists around the globe because of its continuously increasing prevalence worldwide. The emergence of benzothiazole as a prominent lead against diabetes is credited to the development of the aldose reductase inhibitor, Zopolrestat. Since then, there has been a continuous effort to develop benzothiazole derivatives as potential antidiabetic probes, especially in the last two decades. Use of computer aided drug designing tools such as molecular docking and pharmacophore modelling have also played a crucial role in the exploration of efficacy of benzothiazole against other targets for diabetes. In this review, possible targets for benzothiazole against diabetes will be discussed with the brief role each target plays in maintaining the normal blood glucose level in the body. A trend analysis of the emergence of different inhibitors over various intervals of time along with the structure-activity relationship (SAR) studies of benzothiazole as antidiabetic probe is incorporated in the end of the study.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference82 articles.
1. [1] Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030. Diabetes Care 2004, 27, 1047–1053. 2. [2] International Diabetes Federation. http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures (Accessed January 16, 2015). 3. [3] Nomura, S.; Sakamaki, S.; Hongu, M.; Kawanishi, E.; Koga, Y.; Sakamoto, T.; Yamamoto, Y.; Ueta, K.; Kimata, H.; Nakayama, K.; Tsuda-Tsukimoto, M. Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus (1). J. Med. Chem. 2010, 53, 6355–6360. 4. [4] American Diabetes Association. http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/oral-medications/what-are-my-options.html (Accessed January 17, 2015). 5. [5] Shen, D.; Brady, E. J.; Candelore, M. R.; Dallas-yang, Q.; Ding, V. D.; Feeney, W. P.; Jiang, G.; Mccann, M. E.; Mock, S.; Qureshi, S. A.; Saperstein, R.; Shen, X.; Tong, X.; Tota, L. M.; Wright, M. J.; Yang, X.; Zheng, S.; Chapman, K. T.; Zhang, B. B.; Tata, J. R.; Parmee, E. R. Discovery of Novel , Potent, Selective , and Orally Active Human Glucagon Receptor Antagonists Containing a Pyrazole Core. Bioorganic & Medicinal Chemistry Letters 2011, 21, 76–81.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|